CT-guided radiofrequency ablation for 157 cases of lung cancer complicated with pneumothorax

LIU Jiwei; YANG Rui

doi:10.19732/j.cnki.2096-6210.2022.06.006

您当前的位置：

首页 >

文章列表页 >

CT-guided radiofrequency ablation for 157 cases of lung cancer complicated with pneumothorax

更新时间：2025-12-15

- CT-guided radiofrequency ablation for 157 cases of lung cancer complicated with pneumothorax
- Vol. 31, Issue 6, Pages: 591-595(2022)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19732/j.cnki.2096-6210.2022.06.006
  CLC：
- Published Online：28 December 2022，
  
  Published：28 December 2022
- 稿件说明：
移动端阅览
刘继伟,杨瑞. CT引导下射频消融治疗157例肺癌合并气胸并发症的研究[J]. 肿瘤影像学, 2022, 31(6): 591-595 https://doi.

org/10.19732/j.cnki.2096-6210.2022.06.006
刘继伟,杨瑞. CT引导下射频消融治疗157例肺癌合并气胸并发症的研究[J]. 肿瘤影像学, 2022, 31(6): 591-595 https://doi. DOI： 10.19732/j.cnki.2096-6210.2022.06.006.

org/10.19732/j.cnki.2096-6210.2022.06.006 DOI：

摘要

目的：

研究计算机体层成像（computed tomography，CT）引导下射频消融（radiofrequency ablation，RFA）治疗肺癌的气胸发生及其相关风险因素分析。

方法：

纳入2016年6月2020年7月于河南省胸科医院经影像学及病理学检查证实的157例（共196个病灶）肺癌患者，进行228次RFA，按照术后第1、3、6个月的原则进行随访，之后每隔6个月复查1次，以胸部增强CT结果来评判消融效果，同时记录患者的临床资料、死亡率及治疗相关的气胸发生率，随后进行数据分析。

结果：

157例肺癌患者，随访至2021年7月，共27例患者死亡（23例死于肿瘤进展，4例死于肺部感染）。治疗相关的气胸发生共17例（10.82%）。单因素分析结果表明，肿瘤最长径（

=2.22，

=0.03）、肿瘤位置（

=2.85，

=0.004）、穿刺次数（

=2.71，

=0.007）及消融时间（

=2.16，

=0.03）是气胸发生的不利风险因素；多因素分析结果表明，肿瘤位置（OR=0.89，

=0.04）、穿刺次数（OR=0.76，

=0.02）是气胸发生的独立风险因素。

结论：

CT引导下RFA治疗肺癌是一项安全、微创的方法，降低穿刺次数可有效减少治疗相关气胸的发生。

Abstract

Objective:

To study the occurrence of pneumothorax in lung cancer treated by computed tomography (CT)-guided radiofrequency ablation (RFA) and its related risk factors.

Methods:

A total of 157 patients (196 lesions in total) with lung cancer confirmed by imaging and pathological examination in Henan Chest Hosp

ital from June 2016 to July 2020 were included. And 228 RFA patients were followed up according to the principle of 1

3 and 6 months after surgery

and then re-examined every 6 months to evaluate the ablation effect based on the results of chest enhanced CT. Clinical data

mortality

and treatment-related pneumothorax were recorded

followed by data analysis.

Results:

Follow-up was performed to July 2021

and 27 patients were died (23 from tumor progression and 4 from pulmonary infection). Treatment-related pneumothorax occurred in 17 cases (10.82%). Univariate analysis showed that the longest diameter of tumor (

=2.22

=0.03)

tumor location (

=2.85

=0.004)

number of puncture (

=2.71

=0.007) and ablation time (

=2.16

=0.03) were adverse risk factors for the development of treatment-related pneumothorax

while multivariate analysis showed that the location of tumor (OR=0.89

=0.04) and number of puncture (OR=0.76

=0.02) were independent risk factors for the development of treatment-related pneumothorax.

Conclusion:

CT-guided RFA for lung cancer is a safe and minimally invasive method

and reducing the number of puncture can effectively reduce the occurrence of treatment-related pneumothorax.

关键词

Keywords

references

Views

1009

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress in the prediction of lung nodule growth

Multi-region radiomics features from enhanced CT combined with clinical risk factors for preoperative prediction of lymphovascular invasion in colon cancer

The efficacy and safety of ¹⁷⁷Lu-DOTA-IBA in the treatment of bone metastases from lung cancer: a prospective single-arm study

Application value of multimodal imaging technology based on CT and MRI in the diagnosis and PRETEXT staging of childhood hepatoblastoma

The predictive value of CT radiomics model for immunotherapy efficacy in non-small cell lung cancer

Related Author

ZHAO Baolian

XIAO Yi

Wanping LI

Wenbin ZHENG

Xinyi LIN

Wei WANG

Tingting XU

Lin QIU

Related Institution

Department of Radiology, The Second Affiliated Hospital of Shantou University Medical College

Department of Radiology, Puning People's Hospital, Puning

Shantou University Medical School

Targeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province

Institute of Nuclear Medicine, Southwest Medical University

AI问答

⁰